Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

    ... The incidences of grades 3-4 neutropenia , thrombocytopenia , leukopenia, anemia , deep vein thrombosis , ...

    Research Article last updated 11/28/2016 - 9:36am.

  2. Immunosuppressive therapy for transplant-ineligible aplastic anemia patients

    ... infection and hemorrhage due to neutropenia and thrombocytopenia and suffer from symptoms of anemia. The main treatment ...

    Research Article last updated 03/02/2015 - 1:04pm.

  3. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

    ... years, mainly at the expense of neutropenia and thrombocytopenia in the first courses of therapy. At present, the optimal ... response, and 50% incidence of grade 3 and 4 neutropenia and thrombocytopenia compared to del(5q) patients. Recent data suggest that the ...

    Research Article last updated 11/05/2012 - 9:37am.

  4. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    ... in these patients: grades III-IV, mainly hematologic- thrombocytopenia (20 patients) and neutropenia (13 patients). The ...

    Research Article last updated 09/13/2016 - 2:47pm.

  5. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... therapy or for patients with lower-risk MDS who have thrombocytopenia or neutropenia or have anemia that is ...

    Research Article last updated 07/09/2013 - 3:03pm.

  6. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

    ... VAF predicted for monocytosis (P=0.003), RUNX1 VAF with thrombocytopenia (P=0.01) and SF3B1 with ringed sideroblasts (P=0.001). ...

    Research Article last updated 12/08/2015 - 1:04pm.

  7. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

    ... with moderate/severe fibrosis presented with severer thrombocytopenia (p = 0.039) and higher numbers of circulating ...

    Research Article last updated 06/20/2013 - 11:02am.

  8. Myelodysplastic syndromes: a challenging disease for patients and physicians

    ... high risk of rapidly developing neutropenia and thrombocytopenia . Several promising drugs are currently under investigation ...

    Research Article last updated 07/31/2012 - 1:58pm.

  9. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes

    ... degrees of anemia , neutropenia , and thrombocytopenia , and at presentation can range from indolent to life ...

    Research Article last updated 07/31/2012 - 1:03pm.

  10. Decreased plasma cytokines associate with low platelet counts in aplastic anemia and immune thrombocytopenic purpura

    ... than in those with lower platelet counts. In a murine thrombocytopenia model, levels of CD40L, CXCL5, CCL5, and EGF decreased ...

    Research Article last updated 07/30/2012 - 1:53pm.